XML 64 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1
Commitments and Contingencies - Additional Information (Detail)
1 Months Ended 12 Months Ended
Feb. 28, 2018
USD ($)
Nov. 30, 2017
ft²
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2013
USD ($)
Feb. 21, 2018
USD ($)
May 20, 2016
USD ($)
Commitments And Contingencies Disclosure [Line Items]              
Operating lease expiration date     2018-02        
Operating lease rent expense     $ 800,000 $ 700,000      
License fees payable         $ 100,000    
AGC Biologics, Inc              
Commitments And Contingencies Disclosure [Line Items]              
Contractual obligation payments     700,000       $ 3,800,000
AGC Biologics, Inc | Subsequent Event              
Commitments And Contingencies Disclosure [Line Items]              
Contractual obligation payments           $ 5,600,000  
ISU Abxis | Maximum              
Commitments And Contingencies Disclosure [Line Items]              
Potential milestone payments     2,000,000        
Pfizer Inc | Collaboration Agreement | Maximum              
Commitments And Contingencies Disclosure [Line Items]              
Obligated to make milestone and royalty payments upon achievement of clinical, regulatory and commercial milestones     $ 17,500,000        
Pfizer Inc | Subsequent Event | Collaboration Agreement              
Commitments And Contingencies Disclosure [Line Items]              
Milestone payment $ 1,000,000            
South San Francisco, California | New Office Lease Agreement              
Commitments And Contingencies Disclosure [Line Items]              
Leased area | ft²   8,606          
Operating lease term of contract   5 years 2 months          
Operating lease commencement date   Feb. 16, 2018